Published in
American Society for Microbiology, Journal of Virology, 24(96), 2022
DOI: 10.1128/jvi.01730-22
Links
Tools
The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model
Journal article published in 2022 by
Aswath P. Chandrasekar 
,
Nathan W. Cummins ,
Sekar Natesampillai,
Anisha Misra ,
Alecia Alto ,
Greg Laird ,
Andrew D. Badley
,
Nathan W. Cummins ,
Sekar Natesampillai,
Anisha Misra ,
Alecia Alto ,
Greg Laird ,
Andrew D. Badley
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
This study is the first to examine the applicability of BCL-2 inhibition in the setting of active HIV infectionin vivo. Furthermore, this study demonstrates that venetoclax significantly enhances target cell killing induced by Fas ligand, TRAIL, and perforin/granzyme B and synergistically enhances autologous NK and CD8 cells’ killing of target cells.